Hep C Edition.pdf | Page 33

The Impact on Patients and Specialty Pharmacies of Evolving Payer Interventions to Manage Hepatitis C Agents Tucker Hurtado, MPH Fionna Frascella, BS Health Strategies Group The authors report no financial conflicts with any products discussed in this paper. Management of Hepatitis C Treatments is a Top Priority The approval of considerably improved therapies for hepatitis C has radically changed the treatment paradigm for patients while significantly increasing drug expenditures for payers. The nee